Key Highlights

  • Revvity (NYSE:RVTY) reports third quarter results before the market opens on November 3, 2026. Consensus from 16 analysts puts EPS at USD 1.30, in line with the screener.
  • The second quarter beat was substantial: EPS of USD 1.41 landed against USD 1.22 expected, roughly 15.6 percent ahead, while Revenue reached USD 730 million versus USD 720 million a year earlier.
  • Shares rose 41.4 percent from the August 4 report through October 30, while the SPDR S&P 500 ETF Trust (NYSEARCA:SPY) fell 1.5 percent, per published market data.
  • Over the past month one analyst cut estimates and none raised them, so Revvity (NYSE:RVTY) enters the report with a higher share price but flat numbers.

What Is Expected

Consensus EPS of USD 1.30 compares with USD 1.41 reported last quarter and USD 1.06 in the first quarter. Revvity (NYSE:RVTY) beat the second quarter consensus of USD 1.22 by 19 cents, about 15.6 percent, simple arithmetic. Revenue of USD 730 million compares with USD 720 million a year earlier, about 1.4 percent growth, so the beat owed more to margins than volume. A third quarter revenue consensus and company guidance were not verified. Forward price to Earnings on current-year consensus is about 31 per published data; published trailing multiples were inconsistent and are left out. Current-year EPS estimates were unchanged over the last month and up 2.0 percent over three months.

Peer Read Across

Thermo Fisher Scientific (NYSE:TMO) reported on October 21, 2026: revenue of USD 12.14 billion, up 9 percent with 6 percent organic growth, against USD 11.95 billion expected, and adjusted EPS of USD 6.68 against USD 6.40. Its Life Sciences Solutions revenue of USD 2.72 billion, up 5.1 percent, missed the USD 2.84 billion consensus, and Specialty Diagnostics fell 6.5 percent to USD 1.10 billion, below USD 1.16 billion expected. Revvity (NYSE:RVTY) sells into both life science and diagnostics markets, so a strong tools quarter with soft diagnostics is a mixed signal. Thermo's own share reaction was not verified.

Bull and Bear Cases

No options-implied move was found. After a 41.4 percent rise since August, expectations are demanding. A bull case, EPS near or above last quarter's USD 1.41 with steady diagnostics, could extend the run. A bear case, an EPS miss or cautious outlook, could return part of the gain; on the screener market cap of about USD 17.56 billion, unverified, a 5 percent move is about USD 878 million, simple arithmetic. Risks include softer biopharma tool demand, diagnostics pricing and a stock that has already priced improvement. Past beats do not guarantee another, and the scenarios above are illustrations, not predictions. Check the company release for the exact call time.

Where Things Stand

The stock is Revvity (NYSE:RVTY), up 41.4 percent since its August 4 report, and the November 3 hurdle is modest on paper at USD 1.30 against last quarter's USD 1.41. The risk lies in the price: a share gain that large leaves little room for an in-line print. Thermo Fisher's mixed segment results add caution for diagnostics. Watch the guidance, the diagnostics trend and biopharma Demand commentary on the call.